How should clinicians address intratumour heterogeneity in clear cell renal cell carcinoma?More about Open Access at the Crick
Authors listAspasia Soultati Mark Stares Charles Swanton James Larkin Samra Turajlic
Despite the availability of multiple targeted therapies, the 5-year survival rate of patients with metastatic clear cell renal cell carcinoma (ccRCC) rarely exceeds 10%. Recent insights into the mutational landscape and evolutionary dynamics of ccRCC have offered up a plausible explanation for these outcomes. The purpose of this review is to link the research findings to potential changes in clinical practice.
Journal Current Opinion in Urology
Issue number 5